Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23N3O4S.ClH |
| Molecular Weight | 377.887 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O
InChI
InChIKey=PFHZICSPLHQCDZ-UHFFFAOYSA-N
InChI=1S/C15H23N3O4S.ClH/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2;/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21);1H
| Molecular Formula | C15H23N3O4S |
| Molecular Weight | 341.426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6628519
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6628519
Sulpiride is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Sulpiride is a selective antagonist at dopamine D2 and D3 receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Racemic and L-sulpiride significantly decreased stimulated serum gastrin concentration, but they did not affect fasting serum gastrin or basal and stimulated gastric acidity. D-sulpiride significantly decreased gastric acid secretion, without affecting serum gastrin levels.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
10.28 nM [IC50] | ||
Target ID: CHEMBL234 |
66.22 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Eglonyl Approved UseIndications. Acute and chronic psychosis (confusion, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic state, accompanied by lethargy; psychosomatic symptoms (especially for stomach ulcers and duodenal ulcers and hemorrhagic rektokolite). |
|||
| Primary | Eglonyl Approved UseIndications. Acute and chronic psychosis (confusion, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic state, accompanied by lethargy; psychosomatic symptoms (especially for stomach ulcers and duodenal ulcers and hemorrhagic rektokolite). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression. | 2001 |
|
| Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. | 2001 |
|
| Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. | 2001 |
|
| In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. | 2001 Apr |
|
| Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures. | 2001 Apr 2 |
|
| Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. | 2001 Apr 27 |
|
| Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes. | 2001 Aug |
|
| A method to evaluate the diffusion rate of drugs from a microdialysis probe through brain tissue. | 2001 Aug 15 |
|
| A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. | 2001 Aug 3 |
|
| Intra-supraoptic nucleus sulpiride improves anorexia in tumor-bearing rats. | 2001 Aug 8 |
|
| Hypothalamic dopaminergic receptor expressions in anorexia of tumor-bearing rats. | 2001 Dec |
|
| Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. | 2001 Feb |
|
| Evidence for a modulatory role of Ih on the firing of a subgroup of midbrain dopamine neurons. | 2001 Feb 12 |
|
| Changes in striatal electroencephalography and neurochemistry induced by kainic acid seizures are modified by dopamine receptor antagonists. | 2001 Feb 16 |
|
| Negative interaction of dopamine D2 receptor antagonists and GBR 12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. | 2001 Feb 23 |
|
| Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. | 2001 Jan |
|
| Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. | 2001 Jan |
|
| Involvement of D2 dopamine receptors in the opposing effects of two CCK-B agonists in a spatial recognition memory task: role of the anterior nucleus accumbens. | 2001 Jan 1 |
|
| Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. | 2001 Jan 26 |
|
| Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. | 2001 Jan 29 |
|
| [Participation of the dopaminergic brain system in effects of glucocorticoid hormones]. | 2001 Jul |
|
| Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile. | 2001 Jul-Aug |
|
| [Pseudoneurotic schizophrenia: a case report]. | 2001 Jul-Aug |
|
| Pharmacological characterization of the D1- and D2-like dopamine receptors from the brain of the leopard frog, Rana pipiens. | 2001 Jun |
|
| Dopamine D(2)-like receptors selectively block N-type Ca(2+) channels to reduce GABA release onto rat striatal cholinergic interneurones. | 2001 Jun 1 |
|
| Mutant mice lacking the cholecystokinin2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine. | 2001 Jun 22 |
|
| 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. | 2001 Mar |
|
| Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. | 2001 Mar |
|
| Anxiogenic-like effects limit rewarding effects of cocaine in balb/cbyj mice. | 2001 Mar |
|
| Intrapallidal D2 dopamine receptors control globus pallidus neuron activity in the rat. | 2001 Mar 9 |
|
| Dopamine D2-like receptors and amino acid-induced glomerular hyperfiltration in humans. | 2001 May |
|
| Modification of vasomotor symptoms after various treatment modalities in the postmenopause. | 2001 May |
|
| Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. | 2001 Nov |
|
| Dopaminergic modulation of grooming behavior in virgin and pregnant rats. | 2001 Nov |
|
| Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. | 2001 Nov 2 |
|
| Postnatal decrease of sodium current density in rat pituitary melanotropes following the onset of dopaminergic innervation. | 2001 Nov 27 |
|
| Dopaminergic and cholinergic antagonism in a novel-object detection task with rats. | 2001 Nov 29 |
|
| Development of a high-performance liquid chromatographic method for bioanalytical applications with sulpiride. | 2001 Nov 5 |
|
| Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. | 2001 Oct |
|
| The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. | 2001 Oct |
|
| Characterization of the role of medial prefrontal cortex dopamine receptors in cocaine-induced locomotor activity. | 2001 Oct |
|
| Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001 Oct |
|
| Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum. | 2001 Oct 1 |
|
| Potentiation of opioid analgesia in dopamine2 receptor knock-out mice: evidence for a tonically active anti-opioid system. | 2001 Oct 1 |
|
| Hypothalamic CRH mRNA levels are differentially modulated by repeated 'binge' cocaine with or without D(1) dopamine receptor blockade. | 2001 Oct 19 |
|
| Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat. | 2001 Oct 19 |
|
| Modulation of dopamine uptake in rat nucleus accumbens: effect of specific dopamine receptor antagonists and sigma ligands. | 2001 Oct 26 |
|
| [Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. | 2001 Sep |
|
| Physostigmine as treatment for severe CNS anticholinergic toxicity. | 2001 Sep |
|
| Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. | 2001 Sep 15 |
Sample Use Guides
400mg twice daily the doctor may reduce the dose to 200mg twice daily or increase it to a maximum of 1200mg twice daily
Route of Administration:
Oral
CHO-K1 D3R cells (DiscoveRx) were seeded at a density of 5000 cells/well in 384-well black, clear-bottom plates. Following 24 h of incubation, the cells were treated with multiple concentrations of the Sulpiride (0-10 μM) in Hanks’ balanced buffer solution containing 2% DMSO. Following a 10 min preincubation, the cells were next treated with an EC95 dose of dopamine (100 nM) and then incubated at 37 C for 90 min. DiscoveRx reagent (2.5) was then added to cells followed by a 60 min incubation at room temperature. Luminescence was measured on a Hamamatsu FDSS μ-cell reader.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:33:01 GMT 2023
by
admin
on
Sat Dec 16 11:33:01 GMT 2023
|
| Record UNII |
03U3QUS07J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23694-14-6
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
245-826-4
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
DTXSID80946497
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
74586-15-5
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
03U3QUS07J
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY | |||
|
74686-71-8
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
SUPERSEDED | |||
|
3015163
Created by
admin on Sat Dec 16 11:33:01 GMT 2023 , Edited by admin on Sat Dec 16 11:33:01 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
